Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Q
115180
vs
K
KOSPI 200
Over the past 12 months, Qurient Co Ltd has underperformed KOSPI 200, delivering a return of +21% compared to KOSPI 200's +112% growth.
Stocks Performance
115180 vs KOSPI 200
Performance Gap
115180 vs KOSPI 200
Performance By Year
115180 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Qurient Co Ltd
Glance View
Qurient Co Ltd is a South Korean biopharmaceutical company that discovers and develops new medicines, especially for cancer, immune diseases, and infectious diseases. It does not mainly sell finished consumer products; instead, it builds drug candidates in the lab and advances them through clinical testing so they can become approved medicines or licensed programs. Its customers are mainly larger drug companies, hospitals, and ultimately patients who would use its treatments if they win approval. Qurient makes money through research partnerships, licensing deals, milestone payments, and product sales if any of its own drugs reach the market. That mix means its business depends more on scientific progress and drug development deals than on manufacturing volume. What makes Qurient different is that it acts as an early-stage drug developer with a focused pipeline, rather than a broad pharmaceutical seller. In this model, the company creates intellectual property and drug candidates, then partners with bigger pharma groups or advances the drugs itself. The business is high risk, but one successful program can become a valuable asset for years.